PRCT - NASDAQ

PROCEPT BioRobotics Corporation

PRCT·NASDAQ

$26.33

-1.6%

HealthcareMedical - Devices

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.50B

EPS-1.7200

P/E Ratio-15.31

Earnings Date08/05/2026

508.08M

Assets

-5%

3Y+64.0%

5Y+303.0%

10Y+720.0%

142.21M

Total Liabilities

3Y+27.0%

5Y+119.0%

10Y-31.0%

365.87M

Total Equity

-9%

3Y+86.0%

5Y+500.0%

10Y-354.0%

PROCEPT BioRobotics Corporation Funding & Solvency Profile

PRCT · NASDAQ

Current Assets

Cash & Cash Equivalents286.50M

Net Receivables83.53M

Inventory70.69M

Other Current Assets9.65M

Total Current Assets450 M

Non-Current Assets

Property, Plant & Equipment47.94M

Goodwill & Intangible Assets709.00K

Long-Term Investments0.00

Other Non-Current Assets9.06M

Total Non-Current Assets57 M

Total Assets

508.08M

Financial Health Analysis

Current Ratio

6.85x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.39x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

385 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

89% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

PROCEPT BioRobotics Corporation Balance Sheet

PRCT • NASDAQ

PROCEPT BioRobotics Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	286.5M	333.7M	257.2M	222.6M	304.3M	100.1M	42M
Cash & Short-Term Investments	286.5M	333.7M	257.2M	222.6M	304.3M	100.1M	42M
Net Receivables	83.5M	83.5M	48.4M	15.3M	4.5M	1.5M	1.1M
Accounts Receivables	83.5M	83.5M	48.4M	15.3M	4.5M	1.5M	1.1M
Inventory	70.7M	56.2M	39.8M	28.5M	13.1M	7.5M	6.7M
Prepaids	0.0	0.0	0.0	0.0	0.0	744K	552K
Other Current Assets	9.6M	8.5M	5.2M	6.2M	3.4M	0.0	0.0
Total Current Assets	450.4M	481.8M	350.6M	272.6M	326.2M	109.9M	50.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	47.9M	45.7M	49M	32.1M	8.3M	12.9M	8.3M
Intangible Assets	709K	932K	1.2M	1.5M	1.8M	2M	2.3M
Goodwill & Intangible Assets	709K	932K	1.2M	1.5M	1.8M	2M	2.3M
Long-Term Investments	0.0	3M	3M	3M	777K	777K	691K
Other Non-Current Assets	9.1M	2.6M	919K	51K	0.0	356K	378K
Total Non-Current Assets	57.7M	52.2M	54.1M	36.7M	10.9M	16.1M	11.6M
Total Assets	508.1M	534M	404.7M	309.3M	337M	126M	62M
LIABILITIES
CURRENT LIABILITIES
Total Payables	17.3M	10M	13.5M	9.4M	2M	1.2M	1.4M
Accounts Payable	17.3M	10M	13.5M	9.4M	2M	1.2M	1.4M
Accrued Expenses	0.0	21.5M	16.9M	13.4M	6.5M	4.6M	2.3M
Short Term Debt	0.0	1.9M	1.7M	2.1M	2.1M	6.3M	0.0
Tax Payables	0.0	2.1M	1.7M	829K	515K	302K	90K
Deferred Revenue	13M	9.6M	5.7M	2.9M	1M	233K	106K
Other Current Liabilities	35.5M	10.1M	8.2M	7.5M	4.6M	2.2M	2.9M
Total Current Liabilities	65.8M	53.1M	45.9M	35.3M	16.2M	14.5M	6.8M
NON-CURRENT LIABILITIES
Long Term Debt	51.6M	51.5M	51.3M	51.2M	50M	44.4M	23.2M
Other Non-Current Liabilities	24.8M	324K	517K	1.8M	1.7M	2M	175.8M
Total Non-Current Liabilities	76.4M	78.7M	78M	77M	53.7M	50.5M	199M
Capital Lease Obligations	0.0	26.9M	26.2M	24M	2M	4.1M	0.0
Total Liabilities	142.2M	131.8M	124M	112.3M	69.9M	65M	205.8M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	243.9M	0.0
Additional Paid-In Capital	0.0	948.1M	735.2M	545.8M	528.7M	18.8M	4.8M
Retained Earnings	-641.6M	-546M	-454.6M	-348.7M	-261.5M	-201.7M	-148.6M
Accumulated Other Comprehensive Income/Loss	0.0	114K	84K	-6K	-54K	-14K	4K
Other Total Stockholders' Equity	1B	0.0	0.0	0.0	0.0	0.0	-173.1M
Total Stockholders' Equity	365.9M	402.2M	280.8M	197.1M	267.1M	61M	-143.8M
Total Equity	365.9M	402.2M	280.8M	197.1M	267.1M	61M	-143.8M
SUMMARY
Total Liabilities & Equity	508.1M	534M	404.7M	309.3M	337M	126M	62M
Total Investments	0.0	3M	3M	3M	777K	777K	691K
Total Debt	51.6M	80.3M	79.2M	77.3M	54.1M	54.8M	23.2M
Net Debt	-234.9M	-253.5M	-178M	-145.3M	-250.2M	-45.4M	-18.8M
Shares Outstanding	55,878,589	55,878,589	55,878,589	55,878,589	55,878,589	55,878,589	55,878,589

SEC Filings

PRCT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	April 30, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 29, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 22, 2026	June 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 06, 2026	March 05, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 05, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 04, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 18, 2025	September 15, 2025	2025	View Filing

Showing 1 to 10 of 72 filings

Related Guides

Blog Categories

Continue your PRCT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.